This morning, positive results from a phase 2a study testing an experimental asthma drug developed by biotech Regeneron (NASDAQ: REGN ) and big pharma company Sanofi (NYSE: SNY ) were published in the New England Journal of Medicine. In the following video, health-care analyst Max Macaluso discusses the details of the trial and offers his long-term view on both stocks.
While investors have made huge gains with Regeneron in the past 12 months, this is one of many biotech stocks that does not pay a dividend. If you're on the lookout for high-yielding stocks, The Motley Fool has compiled a special free report outlining our nine top dependable dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your copy today at no cost! Just click here.